Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Completed · Phase 1

Conditions studied: Maculopathy, Age-Related

In brief

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).

Key facts

Study ID

NCT00211419

Run by

Manhattan Eye, Ear & Throat Hospital

Last updated by the study team

2012-10-24

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A male or female with evidence of exudative age-related macular degeneration with clinical/angiographic/optical coherence tomography (OCT) findings of subfoveal choroidal neovascularization (CNV) which has not responded to current therapy
• Baseline best-corrected visual acuity (BCVA) 20/40 to 20/640
• Patient must be willing and able to comply with the protocol and provide informed consent.

You may not qualify if…

• Patients on intravenous, subcutaneous, or anticoagulant therapy (with the exception of aspirin and antiplatelet therapy) and cannot take a 5 day holiday from therapy prior to the injection procedure. Note: Patients on oral anticoagulant therapy may be considered to participate if the physician responsible for monitoring the anticoagulant therapy agrees that the patient may take a 5 day holiday from therapy prior to each anecortave injection. The attending doctor must notify the principal investigator and this notification will be made part of the source documentation. Anticoagulant therapy may resume either the evening of or the morning after the injection procedure.
• Patient with known glaucoma or steroid induced ocular hypertension
• Intraocular pressures of 21 mmHg or greater at time of entry into the study
• Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions
• Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye
• Patient participating in any other investigational drug study
• Inability to obtain photographs to document CNV (including difficulty with venous access)
• Concomitant oral steroids or topical ophthalmic steroid use
• Sub-Tenon's injection of steroids within the past 6 months
• Patient with significant liver disease or uremia
• Patient with known adverse reaction to indocyanine green, iodine, verteporfin, or triamcinolone
• Patient is pregnant or nursing
• Age less than 50 years old

Where it is running

• Manhattan Eye, Ear & Throat Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.